Comparative Pharmacology
Head-to-head clinical analysis: MAXALT versus TOSYMRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXALT versus TOSYMRA.
MAXALT vs TOSYMRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve signaling.
Sumatriptan is a selective agonist of serotonin (5-HT1B/1D) receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission.
5 mg or 10 mg orally at onset of migraine; maximum 30 mg in 24 hours (two doses with at least 2 hours between them).
10 mg intranasally as a single dose, may repeat once after 24 hours if needed. Maximum 2 doses in 7 days.
None Documented
None Documented
2-3 hours in plasma; clinical effect correlates with distribution to CNS rather than plasma half-life.
Terminal elimination half-life approximately 2.5 hours; clinically relevant for dosing every 4-6 hours.
Renal (60% as unchanged drug and metabolites) and fecal (40% primarily as metabolites).
Renal excretion of unchanged drug and metabolites; 70% recovered in urine as parent and metabolites, 30% in feces.
Category C
Category C
Antimigraine Agent
Antimigraine Agent